Immune-Cell Neighborhoods in Autoimmune Disease: Mechanisms, Clinical Relevance, and Therapeutic Implications

Abstract

The concept of immune-cell neighborhoods, defined as localized microenvironments with distinct cellular compositions and interactions, has transformed the understanding of autoimmune pathogenesis. Recent advances in spatial transcriptomics and single-cell technologies have revealed that the spatial arrangement and crosstalk among immune cells within tissues play crucial roles in the initiation, maintenance, and progression of autoimmune diseases. This review synthesizes current evidence on immune-cell neighborhoods across various autoimmune conditions, elucidates mechanisms underlying disease heterogeneity, and discusses their clinical and therapeutic implications. Emphasis is placed on emerging therapies targeting cellular interactions and compartmentalized inflammation, as well as guideline-based recommendations for integrating these advances into patient care.

Introduction

Autoimmune diseases are characterized by aberrant immune responses against self-antigens, leading to chronic inflammation and tissue destruction. Traditional views focused on the types and quantities of infiltrating immune cells; however, recent insights highlight the significance of their spatial organization within tissues. Immune-cell neighborhoods, comprising distinct clusters of T cells, B cells, antigen-presenting cells, and stromal elements, orchestrate local immune responses, influencing clinical phenotypes and therapeutic outcomes. Understanding the functional architecture and dynamics of these microenvironments is essential for developing targeted interventions and advancing precision medicine in autoimmunity.

Epidemiology / Disease Burden

Autoimmune diseases collectively affect up to 5-8% of the global population, with increasing incidence observed over recent decades. Conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and type 1 diabetes (T1D) impose substantial morbidity, disability, and healthcare costs. The burden varies geographically and demographically, often with a female predominance and variable age of onset. The heterogeneity in clinical presentation is mirrored by differences in immune-cell neighborhoods within affected organs, contributing to the complexity of disease management and prognosis.

Pathophysiology

Autoimmune pathology is driven not only by the presence of autoreactive lymphocytes but also by their organization into specialized niches within tissues. For example, ectopic lymphoid structures (ELS) in RA synovium or MS brain parenchyma contain aggregates of T cells, B cells, follicular dendritic cells, and other myeloid populations. These neighborhoods foster antigen presentation, somatic hypermutation, and cytokine production, sustaining local inflammation. Advances in spatial transcriptomics have delineated unique gene expression profiles within these niches, revealing pathways mediating tissue damage and resistance to immunosuppression. Interactions between immune cells and resident stromal or endothelial cells further modulate local immune tone, emphasizing the microenvironment's role in shaping disease trajectory.

Risk Factors

Genetic predisposition, environmental exposures, and host factors influence the development and evolution of pathogenic immune-cell neighborhoods. Human leukocyte antigen (HLA) alleles, particularly HLA-DR and HLA-DQ variants, confer susceptibility to multiple autoimmune diseases by affecting antigen presentation and T cell selection. Environmental triggers such as infections, smoking, and dysbiosis of the microbiome can initiate or perpetuate aberrant immune activation. Additionally, age, sex hormones, and epigenetic modifications modulate the composition and function of immune-cell neighborhoods, impacting disease onset and progression.

Clinical Features

The clinical manifestations of autoimmune diseases reflect the heterogeneity of immune-cell neighborhoods within affected tissues. For instance, in SLE, renal biopsies may reveal variable degrees of lymphoid aggregation correlating with nephritis severity. In MS, compartmentalized meningeal inflammation with B cell-rich aggregates is linked to cortical demyelination and neurodegeneration. Such microenvironmental diversity underpins differences in disease course, therapeutic responsiveness, and risk of complications. Recognizing the patterns of immune-cell organization can aid in disease stratification and inform personalized management strategies.

Diagnosis

Diagnosis of autoimmune diseases increasingly incorporates histopathological and molecular assessment of immune-cell neighborhoods. Immunohistochemistry, multiplex immunofluorescence, and spatial transcriptomics enable precise characterization of cellular subsets and their spatial relationships within biopsies. These technologies facilitate identification of ELS, tertiary lymphoid organs, and cellular clusters associated with disease activity or therapeutic resistance. Integration of spatial immune profiling with serological and imaging modalities enhances diagnostic accuracy and prognostication, offering a more nuanced understanding of disease heterogeneity.

Treatment & Management

Current therapies for autoimmune disease, including glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologics, target broad immune pathways but variably impact localized immune-cell neighborhoods. Agents such as B cell-depleting therapies (e.g., rituximab) or cytokine inhibitors (e.g., anti-TNF, anti-IL-6) may disrupt pathogenic niches, particularly in patients with dense lymphoid aggregates. Optimizing treatment requires understanding the spatial and functional context of immune-cell interactions, as well as monitoring the persistence or resolution of inflammatory neighborhoods during therapy. Multidisciplinary care and individualized treatment plans are essential for addressing the diverse clinical sequelae stemming from varied tissue microenvironments.

Recent Advances / Emerging Therapies

Technological innovations have enabled unprecedented spatial and functional dissection of immune-cell neighborhoods in autoimmunity. Single-cell RNA sequencing, imaging mass cytometry, and multiplexed spatial transcriptomics have revealed novel cell subsets, interaction networks, and signaling pathways within diseased tissues. Emerging therapies aim to selectively modulate microenvironmental signals, such as chemokine receptor antagonists, costimulatory blockade, and targeted delivery of immunomodulators to specific cellular clusters. Additionally, strategies to reprogram stromal or endothelial cells that support pathogenic neighborhoods hold promise for durable remission. Clinical trials are underway to evaluate the efficacy and safety of these approaches in patients with refractory or relapsing disease phenotypes.

Guideline Recommendations

Contemporary guidelines from rheumatology, neurology, and immunology societies increasingly emphasize the need for tissue-based assessment and personalized therapy in autoimmune disease management. Recommendations highlight the utility of biopsy and advanced imaging for characterizing immune-cell neighborhoods, particularly in atypical or treatment-resistant cases. Integration of spatial immune profiling into clinical practice requires interdisciplinary collaboration and robust standardization of techniques. Ongoing education and research are essential for translating mechanistic insights into effective, individualized care for patients with complex autoimmunity.

Conclusion

Immune-cell neighborhoods represent a critical frontier in the understanding and management of autoimmune diseases. Their spatial architecture and cellular interactions dictate disease mechanisms, clinical heterogeneity, and therapeutic responses. Advances in molecular profiling and targeted interventions offer new avenues for precision medicine, moving beyond traditional paradigms of immune modulation. Continued research into the dynamics of immune-cell neighborhoods will enhance the ability of clinicians to diagnose, stratify, and treat autoimmune diseases with greater specificity and efficacy.